We are live on ! Find out more
MLNT

Melinta Therapeutics
MLNT

Delisted

MLNT was delisted on the 10th of January, 2020.

86 hedge funds and large institutions have $245M invested in Melinta Therapeutics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 12 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,511% more capital inflows, than outflows

Capital inflows: $148M | Capital outflows: $3.2M

225% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 12

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

9.47% more ownership

Funds ownership: 58.67% → 68.14% (+9.5%)

4% more funds holding

Funds holding: 83 → 86 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less call options, than puts

Call options by funds: $695K | Put options by funds: $706K

Holders
86
Holders Change
+3
Holders Change %
+3.61%
% of All Funds
1.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
39
Reduced
12
Closed
15
Calls
$695​K
Puts
$706​K
Net Calls
-⁠$11​K
Net Calls Change
+$684​K

MLNT Hedge Fund Activity: Q2 2018 in Review

86 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics (MLNT) for Q2 2018, worth a combined $245M — up 80% from $136M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new MLNT positions and 15 closed out — a net gain of 3 holders — while 39 added to existing stakes and 12 trimmed.

The largest buyer was Oikos Holdings, adding an estimated $56.7M. The largest seller was Man Group, exiting entirely with an estimated $1.14M sold.

  • 86 institutional investors held Melinta Therapeutics (MLNT) as of Q2 2018, up from 83 in Q1 2018.
  • Funds reported $245M of Melinta Therapeutics stock for Q2 2018, up 80% quarter-over-quarter.
  • 18 funds opened new Melinta Therapeutics positions in Q2 2018 and 15 closed out, a net change of +3 holders.
  • The largest Melinta Therapeutics buyer in Q2 2018 was Oikos Holdings, an estimated $56.7M added.
  • The largest Melinta Therapeutics seller in Q2 2018 was Man Group, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2018.